1. Short title This Act may be cited as the FDA Accountability for Public Safety Act . 2. Approval against the recommendation of the FDA advisory committee on opioid drugs (a) In General Any approval of an application or supplement to an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b) ) for a drug that is an opioid against the recommendation of the advisory committee pursuant to section 106 of the Comprehensive Drug and Recovery Act of 2016 ( Public Law 114–198 ) shall be made by the Commissioner of Food and Drugs (referred to in this section as the Commissioner ) and shall not be delegated. (b) Reports to Congress If the Commissioner approves a drug as described in subsection (a), the Commissioner shall— (1) submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, and to any member of Congress that requests the report, that includes— (A) medical and scientific evidence regarding patient safety that clearly supports the Commissioner's decision to approve the opioid drug against the recommendation of the advisory committee; and (B) a disclosure of any potential conflicts of interest that may exist regarding any official of the Food and Drug Administration who was involved in the decision to approve the drug prior to the Commissioner's final decision under subsection (a)